| Title: |
Bradykinin Contributes to the Vasodilator Effects of Chronic Angiotensin-Converting Enzyme Inhibition in Patients With Heart Failure |
| Authors: |
Witherow, Fraser N.; Helmy, Ahmed; Webb, David J.; Fox, Keith A.A.; Newby, David E. |
| Source: |
Circulation ; volume 104, issue 18, page 2177-2181 ; ISSN 0009-7322 1524-4539 |
| Publisher Information: |
Ovid Technologies (Wolters Kluwer Health) |
| Publication Year: |
2001 |
| Description: |
Background Bradykinin, an endogenous vasodilator peptide, is metabolized by ACE. The aims of the present study were to determine the doses of B9340, a bradykinin receptor antagonist, that inhibit vasodilatation to exogenous bradykinin and to assess the contribution of bradykinin to the maintenance of basal vascular tone in patients with heart failure receiving chronic ACE inhibitor therapy. Methods and Results Forearm blood flow was measured using bilateral venous occlusion plethysmography. On three occasions in a double-blind randomized manner, 8 healthy volunteers received intrabrachial infusions of placebo or B9340 (at 4.5 and 13.5 nmol/min). On each occasion, placebo or B9340 was coinfused with bradykinin (30 to 3000 pmol/min) and substance P (4 to 16 pmol/min). B9340 caused no change in basal FBF but produced dose-dependent inhibition of the vasodilatation to bradykinin ( P |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1161/hc4301.098252 |
| Availability: |
https://doi.org/10.1161/hc4301.098252; https://www.ahajournals.org/doi/full/10.1161/hc4301.098252 |
| Accession Number: |
edsbas.7ABB2A91 |
| Database: |
BASE |